Embla Medical hfOSSFF 92 ROE % is 6.46% as of Mar. 2026, which is 37% below its 10-year median of 10.29. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.49. The stock has 2 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Embla Medical hf ranks better than 73.59% on this metric.
The historical rank and industry rank for Embla Medical hf's ROE % or its related term are showing as below:
OSSFF'
s ROE % Range Over the Past 10 Years
Min: 1.04 Med: 10.29 Max: 15.73
Current: 9.84
During the past 13 years, Embla Medical hf's highest ROE % was 15.73%. The lowest was 1.04%. And the median was 10.29%.
OSSFF's ROE % is ranked better than 73.59% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs OSSFF: 9.84
Embla Medical hf (OTCPK:OSSFF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Embla Medical hf ROE % Related Terms
Embla Medical hf ROE % Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's ROE % distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Embla Medical hf (OSSFF) has a ROE % of 6.46% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Embla Medical hf and its competitors. This is 37% below median its historical median of 10.29. Over the past decade, Embla Medical hf's ROE % has ranged from 1.04 to 15.73. According to the industry distribution chart, Embla Medical hf ranks #211 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 26.4%.
Is Embla Medical hf's ROE % too high?
Embla Medical hf's current ROE % of 6.46% is 37% below median its 10-year median of 10.29. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 15.73. The Medical Devices & Instruments industry median ROE % is 2.42. Embla Medical hf's value of 6.46% is 166.9% above this industry median. Based on the distribution chart, Embla Medical hf ranks #211 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #211 out of 799 companies for ROE %. This puts Embla Medical hf in the upper half of its industry. The industry median ROE % is 2.42. Embla Medical hf's value of 6.46% is 166.9% above this benchmark. Historically, Embla Medical hf's own ROE % has ranged from 1.04 to 15.73 over the past decade. While the company's 10-year median is 10.29 vs. the industry median of 2.42, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current ROE % of 6.46% is 166.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current ROE % is 6.46%, which is 37% below median its own 10-year median of 10.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current ROE % of 6.46%. The stock's GF Value™ is $5.49, compared to a current price of $4.15 — trading 24.4% below its estimated fair value. The current ROE % is 6.46%, which is 37% below median its 10-year median of 10.29 and 166.9% above the Medical Devices & Instruments industry median of 2.42. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current ROE % is 6.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 24.4% below its estimated GF Value™ of $5.49.
Key valuation signals for OSSFF:
ROE %: 6.46% (37% below median its 10-year median of 10.29)
GF Value™: $5.49 vs. price of $4.15 (24.4% below fair value)
Industry Position: 166.9% above the Medical Devices & Instruments median (#211 of 799)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
